Welcome to our dedicated page for VERADERMICS news (Ticker: MANE), a resource for investors and traders seeking the latest updates and insights on VERADERMICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VERADERMICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VERADERMICS's position in the market.
Veradermics (NYSE: MANE) announced new subgroup data from its randomized, double-blind, placebo-controlled Phase 2/3 Study ‘302’ evaluating VDPHL01, an extended-release oral minoxidil tablet, in over 500 males with mild-to-moderate pattern hair loss.
The analysis examines efficacy and safety by age (<40 vs ≥40 years). Results were presented in a poster on July 16, 2026, and will be highlighted in an oral session on July 17, 2026, at the 2026 AAD Innovation Academy in New York City. According to Veradermics, VDPHL01 is part of an extensive program targeting approval for both male and female pattern hair loss, with topline male Study ‘302’ results already reported, Phase 3 male Study ‘304’ fully enrolled with topline data expected in 2H 2026, and female trials ‘207’ and ‘306’ providing topline data timing through 1H 2027.
Veradermics (NYSE: MANE) reported positive topline results from Study ‘207’, an open-label Phase 2 trial of oral extended-release minoxidil candidate VDPHL01 in women with mild-to-moderate pattern hair loss. Participants received 4.5 mg once daily or twice daily for six months.
At Month 6, mean non-vellus target area hair count increased by 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily), with 88.9% and 90.0% of patients, respectively, reporting ‘improved’ or ‘much improved’ hair coverage on the AAIRS. Investigators graded 100% and 90% of participants as improved at Month 6. Fast onset was observed by Month 2. VDPHL01 was generally well tolerated, with no treatment-related SAEs and no cardiac AESIs. According to Veradermics, Study ‘207’ provides proof-of-concept on endpoints used in registration-directed Phase 2/3 Study ‘306’, with topline data expected in 1H 2027.
Veradermics (NYSE: MANE) announced it will host an investor conference call and live webcast on Wednesday, July 15, 2026 at 8:00 a.m. ET. The event will review results from the female treatment arms of Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss.
The call, accompanying slides and a replay will be available via the Events page in the Investors section of Veradermics’ website.
Veradermics (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for pattern hair loss, will participate in two June investor conferences.
Management will present at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference, with live webcasts and 30-day replays on the investor relations site.
Veradermics (NYSE: MANE) will present topline results from the Phase 2/3 ‘302’ study of VDPHL01 at the 2026 World Congress for Hair Research on May 30, 2026. The trial evaluates an extended-release oral minoxidil tablet in over 500 males with pattern hair loss.
According to Veradermics, previously shared positive topline results from Part A may support VDPHL01 as a potential first FDA-approved oral pill for pattern hair loss in nearly 30 years.
Veradermics (NYSE: MANE) announced two E-poster presentations on its investigational extended-release oral minoxidil tablet VDPHL01 at the 2026 Music City SCALE Symposium in Nashville, running May 14–17, 2026.
Posters compare Phase 2 male AGA data for VDPHL01 with existing oral and topical minoxidil, using blinded dermatologist assessments and the AI-based Global HairMap™ (SOCAi) platform.
Veradermics (NYSE: MANE) reported Q1 2026 results and key clinical progress for VDPHL01, its oral treatment for pattern hair loss. Positive topline Phase 2/3 Study ‘302’ data in men showed robust hair growth and placebo-like safety. Enrollment milestones were reached across male and female trials.
The company raised about $766.8 million in 2026 through an upsized IPO and follow-on financing, with pro forma cash expected to fund operations into 2030. Q1 2026 R&D expenses were $20.9 million, G&A $8.9 million, and net loss $27.2 million.
Veradermics (NYSE:MANE) priced an upsized public offering of 3,843,790 common shares at $100.00 per share, raising approximately $384.4 million gross; offering expected to close on May 1, 2026. The company also agreed a private placement of 300,000 pre-funded warrants for about $30.0 million, closing subject to customary conditions.
An underwriter option of 576,568 additional shares is available for 30 days; several banks are acting as bookrunners and placement agents.
Veradermics (NYSE: MANE) launched a proposed public offering of 3,350,000 securities consisting of common stock and, for certain investors, pre-funded warrants, with an underwriter option for an additional 502,500 shares.
The company expects a concurrent private placement of pre-funded warrants to entities affiliated with Suvretta Capital; total securities to be issued across both transactions remain 3,350,000. The registration statement is filed but not yet effective and the offering is subject to market conditions.
Veradermics (NYSE: MANE) reported topline Phase 2/3 Part A results for oral VDPHL01 in male pattern hair loss, from a 519-patient randomized trial. VDPHL01 met all primary and key secondary endpoints, showing mean non-vellus TAHC increases of 30.3 (QD) and 33.0 hairs/cm² (BID) versus 7.3 hairs/cm² placebo at Month 6.
Patient-reported improvements were 79.3% (QD) and 86.0% (BID) versus 35.6% placebo; statistically significant separation occurred as early as Month 2. Safety profile showed no treatment-related SAEs or cardiac AESIs.